1cP-AL-LAD
1-cyclopropanoyl-N6-allyl-6-norlysergic acid diethylamide
1Provenance card
the boundary, as counts
Sources
3429 with DOI
7 strong · 23 moderate · 4 weak
Compilations
12026-05-11T07:00:37.098Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
31last ruled 2026-06-04
0 awaiting a ruling
Issued documents
62026-10-19T20:28:31.849Z
notice · info card · emergency
Searches
243 with no results
queries and counts on the build
Claims checked
7262 supported
62 supported · 10 not
Correspondence
0received
consent field ships in Phase 4
Edges
250
derivations recorded for this entity
Complete over 34 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/1cp-al-lad/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued emergency
- 2026-10-19issueIssued info_card
- 2026-10-19issueIssued notice
- 2026-09-07srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
- 2026-09-07srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
- 2026-09-07srcReturn of the lysergamides. Part III: Analytical characterization of ETH-LAD and 1P-ETH-LAD
- 2026-09-07srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
- 2026-09-07srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
- 2026-09-07srcPharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration
- 2026-09-07srcReturn of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)
- 2026-09-07srcAnalytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
- 2026-09-07srcAnalytical profile of the lysergamide 1cP-AL-LAD and detection of impurities
- 2026-09-07srcAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)
- 2026-09-07srcOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
- 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
- 2026-09-07srcIn vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures
- 2026-09-07srcIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
- 2026-09-07srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
- 2026-09-07srcStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
- 2026-09-07srcPharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor
- 2026-09-07srcHallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases
- 2026-09-07srcPrevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
- 2026-09-07srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
- 2026-09-07srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
- 2026-09-07src5-HT2A receptors: Pharmacology and functional selectivity
- 2026-09-07srcHallucinogen persisting perception disorder: what do we know after 50 years?
- 2026-09-07srcDirect comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects
- 2026-09-07srcComparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants
- 2026-09-07srcMarked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study
- 2026-09-07srcStimulant and hallucinogenic novel psychoactive substances; an update
- 2026-09-07srcKetanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants
- 2026-09-07srcPsychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective
- 2026-09-07srcLysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain
- 2026-09-07srcLysergamides revisited
- 2026-09-07src1cP-LSD Ban - The German NpSG 2021 revision
- 2026-09-07src1cP-AL-LAD - PubChem CID 162368406
- 2026-09-07src1cP-AL-LAD - PsychonautWiki
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-11revisionRevision 1
- 2026-05-11absenceSearched Multiple sources for "1cP-AL-LAD vs 1cP-LSD vs 1P-AL-LAD comparison" — no results
- 2026-05-11absenceSearched ClinicalTrials.gov for "AL-LAD lysergamide psychedelic" — no results
- 2026-05-11absenceSearched PubChem for "1cP-AL-LAD" — no results
- 2026-05-11genGeneration — pipeline-v5 · with 2 morepipeline-v5
- 2026-05-11rungeneration run
The same entries, as forms: six forms.